Evidence map›Paper›PMID 41483434›Full record

ArticleDigestive diseases and sciences2026

Increased Autoimmunity Burden Is a Risk Factor for Developing Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease.

Andrew Chang, Bita Shahrvini, Janice Oh, Divya P Prajapati, Mark Baniqued, Rhett Harmon, Alexandra C Greb, Nirupama Bonthala, Jenny S Sauk, Andrea Shin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrew ChangDepartment of Medicine, UCLA School of Medicine, Los Angeles, CA, USA. andchang@mednet.ucla.edu.
Bita ShahrviniDepartment of Medicine, UCLA School of Medicine, Los Angeles, CA, USA.
Janice OhVatche and Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA.
Divya P PrajapatiDepartment of Medicine, UCLA School of Medicine, Los Angeles, CA, USA.
Mark BaniquedDepartment of Medicine, Olive View UCLA, Sylmar, CA, USA.
Rhett HarmonDepartment of Medicine, Olive View UCLA, Sylmar, CA, USA.
Alexandra C GrebDepartment of Medicine, UCLA School of Medicine, Los Angeles, CA, USA.
Nirupama BonthalaVatche and Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA.
Jenny S SaukVatche and Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA.
Andrea ShinVatche and Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA.
Lin ChangVatche and Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA.
Berkeley N LimketkaiVatche and Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA significant proportion of patients with inflammatory bowel disease (IBD) continue to experience gastrointestinal symptoms despite achieving endoscopic remission. These irritable bowel syndrome (IBS)-like symptoms may result from gut-brain axis dysfunction or low-grade immune activation.

aimsWe aimed to determine whether extra-intestinal autoimmune comorbidities are associated with IBS-like symptoms in quiescent IBD.

methodsWe conducted a retrospective cohort study of adult patients with IBD with endoscopic remission, excluding patients with prior IBS or less than 12 months of follow-up. The primary outcome was the development of IBS-like symptoms within 12 months of baseline colonoscopy. Multivariable Cox regression and Kaplan-Meier survival analysis were used to identify risk factors and assess time to symptom development.

resultsAmong 399 patients, 80 (20.1%) developed new IBS-like symptoms within one year of achieving endoscopic remission. Mean time to symptom onset was 169.2 days (SD 110.3). Symptom development was significantly associated with extra-intestinal autoimmune comorbidities (HR 2.05; 95% CI 1.15-3.66; p = 0.015) and anxiety (HR 1.87; 95% CI 1.13-3.12; p = 0.016). Kaplan-Meier analysis showed that patients with autoimmune comorbidities had a significantly higher cumulative incidence of IBS-like symptoms compared to those without (log-rank p < 0.001).

conclusionAmong patients with IBD with endoscopic remission at baseline, 20.1% developed IBS-like symptoms within one year. The presence of autoimmune comorbidity was significantly associated with earlier development of IBS-like symptoms. These findings suggest that immune system dysregulation may play a role in persistent gastrointestinal symptoms and highlight the need for further research into the pathophysiology of IBS-like symptoms in quiescent IBD.

Indexed as

Autoimmune DiseasesInflammatory Bowel DiseasesIrritable Bowel SyndromeSymptom BurdenAdultColonoscopyComorbidityFemaleFollow-Up StudiesHumansIncidenceLongitudinal StudiesMaleMiddle AgedRemission InductionRetrospective StudiesAutoimmune comorbiditiesInflammatory bowel diseaseIrritable bowel syndromeIrritable bowel syndrome-like symptoms

Identifiers

PMID41483434
PMCPMC13357454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.